Bifidobacterium in anticancer immunochemotherapy: friend or foe?

Abstract

The gut microbiome has received a crescendo of attention in recent years due to myriad influences on human pathophysiology, including cancer. Anticancer therapy research is constantly looking for new hints to improve response to therapy while reducing the risk of relapse. In this scenario, Bifidobacterium, which inhabits the gut microbial ecosystem (especially that of children) and is considered a health-associated microbe, has emerged as a key target to assist anticancer treatments for a better prognosis. However, some researchers have recently hypothesized an unfavorable role of Bifidobacterium spp. in anticancer immunochemotherapy, leading to some confusion in the field. This narrative review summarizes the current knowledge on the role of Bifidobacterium spp. in relation to anticancer treatments, discussing the pros and cons of its presence in the gut microbiome of cancer patients. The current intervention strategies based on the administration of probiotic strains of Bifidobacterium are then discussed. Finally, the need to conduct further studies, especially functional ones, is underlined to provide robust experimental evidence, especially on the underlying molecular mechanisms, and thus resolve the controversies on this microbe for the long-term success of immunochemotherapy.

Keywords

Bifidobacterium / anti-inflammatory / pro-inflammatory / lactate / cancer / immunochemotherapy / response to therapy

References

[1] Henry T. Recherches sur la flore intestinale des nourrissons:(état normal et pathologique). Available from: https://books.google.com.hk/books/about/Recherches_sur_la_flore_intestinale_des.html?id=jrdkcgAACAAJ&redir_esc=y. [Last accessed on 5 Jul 2023]

[2] Sakanaka M,Yoshida K.Varied pathways of infant gut-associated bifidobacterium to assimilate human milk oligosaccharides: prevalence of the gene set and its correlation with bifidobacteria-rich microbiota formation.Nutrients2019;12:71 PMCID:PMC7019425

[3] Alberoni D,Baffoni L,Biavati B.Bifidobacterium xylocopae sp. nov. and bifidobacterium aemilianum sp. nov., from the carpenter bee (xylocopa violacea) digestive tract.Syst Appl Microbiol2019;42:205-16

[4] Modesto M,Bonetti A.Bifidobacterium primatium sp. nov., bifidobacterium scaligerum sp. nov., bifidobacterium felsineum sp. nov. and bifidobacterium simiarum sp. nov.: four novel taxa isolated from the faeces of the cotton top tamarin (saguinus oedipus) and the emperor tamarin (saguinus imperator).Syst Appl Microbiol2018;41:593-603

[5] Macpherson AJ,Ganal-Vonarburg SC.How nutrition and the maternal microbiota shape the neonatal immune system.Nat Rev Immunol2017;17:508-17

[6] Stewart CJ,O'Brien JL.Temporal development of the gut microbiome in early childhood from the TEDDY study.Nature2018;562:583-8 PMCID:PMC6415775

[7] Odamaki T,Sugahara H.Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study.BMC Microbiol2016;16:90 PMCID:PMC4879732

[8] Hopkins MJ.Changes in predominant bacterial populations in human faeces with age and with clostridium difficile infection.J Med Microbiol2002;51:448-54

[9] Woodmansey EJ,Macfarlane GT.Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.Appl Environ Microbiol2004;70:6113-22 PMCID:PMC522128

[10] Biagi E,Rampelli S.Gut microbiota and extreme longevity.Curr Biol2016;26:1480-5

[11] Biagi E,Turroni S,Candela M.The gut microbiota of centenarians: signatures of longevity in the gut microbiota profile.Mech Ageing Dev2017;165:180-4

[12] Rampelli S,D'Amico F.Shotgun metagenomics of gut microbiota in humans with up to extreme longevity and the increasing role of xenobiotic degradation.mSystems2020;5:e00124-20 PMCID:PMC7093822

[13] Rivière A,Lantin D,De Vuyst L.Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut.Front Microbiol2016;7:979 PMCID:PMC4923077

[14] Koh A,Kovatcheva-Datchary P.From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites.Cell2016;165:1332-45

[15] Milani C,Duranti S.Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut.Sci Rep2015;5:15782 PMCID:PMC4623478

[16] Wong CB,Xiao JZ.Insights into the reason of human-residential bifidobacteria (HRB) being the natural inhabitants of the human gut and their potential health-promoting benefits.FEMS Microbiol Rev2020;44:369-85 PMCID:PMC7326374

[17] Sugahara H,Hashikura N,Xiao JZ.Differences in folate production by bifidobacteria of different origins.Biosci Microbiota Food Health2015;34:87-93 PMCID:PMC4654071

[18] D’Aimmo MR,Biavati B,Andlid T.The potential of bifidobacteria as a source of natural folate.J Appl Microbiol2012;112:975-84

[19] Jacob RA.Folate, DNA methylation, and gene expression: factors of nature and nurture.Am J Clin Nutr2000;72:903-4

[20] Meng D,Salviati E.Indole-3-lactic acid, a metabolite of tryptophan, secreted by bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine.Pediatr Res2020;88:209-17 PMCID:PMC7363505

[21] Hubbard TD,Bisson WH.Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles.Sci Rep2015;5:12689 PMCID:PMC4522678

[22] Lanz TV,Mohapatra SR,Wick W.Suppression of Th1 differentiation by tryptophan supplementation in vivo.Amino Acids2017;49:1169-75

[23] Lim HJ.Antimicrobial and immunomodulatory effects of bifidobacterium strains: a review.J Microbiol Biotechnol2020;30:1793-800 PMCID:PMC9728261

[24] Kovanda L,Wei X.In vitro antimicrobial activities of organic acids and their derivatives on several species of gram-negative and gram-positive bacteria.Molecules2019;24:3770 PMCID:PMC6832434

[25] Fukuda S,Hase K.Bifidobacteria can protect from enteropathogenic infection through production of acetate.Nature2011;469:543-7

[26] Yao S,Wang W.Bifidobacterium longum: protection against inflammatory bowel disease.J Immunol Res2021;2021:8030297 PMCID:PMC8324359

[27] Wieërs G,Van Den Driessche M.Do probiotics during in-hospital antibiotic treatment prevent colonization of gut microbiota with multi-drug-resistant bacteria? A randomized placebo-controlled trial comparing saccharomyces to a mixture of lactobacillus, bifidobacterium, and saccharomyces.Front Public Health2020;8:578089 PMCID:PMC7982943

[28] Hevia A,López P.Allergic patients with long-term asthma display low levels of bifidobacterium adolescentis.PLoS One2016;11:e0147809 PMCID:PMC4739579

[29] Gao X,Xie L,Feng L.Obesity in school-aged children and its correlation with gut e.coli and bifidobacteria: a case-control study.BMC Pediatr2015;15:64 PMCID:PMC4448301

[30] Taverniti V.Methodological issues in the study of intestinal microbiota in irritable bowel syndrome.World J Gastroenterol2014;20:8821-36 PMCID:PMC4112874

[31] Murri M,Gomez-Zumaquero JM.Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study.BMC Med2013;11:46 PMCID:PMC3621820

[32] Groeger D,Murphy EF.Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.Gut Microbes2013;4:325-39 PMCID:PMC3744517

[33] Agrawal A,Morris J.Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.Aliment Pharmacol Ther2009;29:104-14

[34] Corrêa NB,Penna FJ,Nicoli JR.A randomized formula controlled trial of bifidobacterium lactis and streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants.J Clin Gastroenterol2005;39:385-9

[35] Plummer S,Harris JC,Hunter J.Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of c. difficile diarrhoea.Int Microbiol2004;7:59-62.

[36] Lin HC,Chen HL.Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial.Pediatrics2008;122:693-700

[37] Singh A,Gosoniu ML.Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial.Eur J Clin Nutr2013;67:161-7

[38] López P,Rodríguez-Carrio J.Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients.Sci Rep2016;6:24072 PMCID:PMC4820712

[39] Yeşilova Y,Akdeniz N.Effect of probiotics on the treatment of children with atopic dermatitis.Ann Dermatol2012;24:189-93 PMCID:PMC3346910

[40] D’Amico F,Tavella T,Brigidi P.Host microbiomes in tumor precision medicine: how far are we?.Curr Med Chem2022;29:3202-30

[41] Roy S.Microbiota: a key orchestrator of cancer therapy.Nat Rev Cancer2017;17:271-85

[42] Viaud S,Zoubir M.Cyclophosphamide induces differentiation of Th17 cells in cancer patients.Cancer Res2011;71:661-5

[43] Viaud S,Mignot G.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.Science2013;342:971-6 PMCID:PMC4048947

[44] Daillère R,Waldschmitt N.Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects.Immunity2016;45:931-43

[45] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[46] Matson V,Bao R.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.Science2018;359:104-8 PMCID:PMC6707353

[47] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[48] Vétizou M,Daillère R.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015;350:1079-84 PMCID:PMC4721659

[49] Motzer RJ,McDermott DF.Checkmate 025 investigatorsNivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13 PMCID:PMC5719487

[50] Borghaei H,Horn L.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med2015;373:1627-39 PMCID:PMC5705936

[51] Carbone DP,Paz-Ares L.CheckMate 026 InvestigatorsFirst-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.N Engl J Med2017;376:2415-26 PMCID:PMC6487310

[52] Le DT,Wang H.PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med2015;372:2509-20

[53] Sharma P.The future of immune checkpoint therapy.Science2015;348:56-61

[54] Chaput N,Coutzac C.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.Ann Oncol2017;28:1368-79

[55] Ascierto PA,Robert C.Survival outcomes in patients with previously untreated braf wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial.JAMA Oncol2019;5:187-94 PMCID:PMC6439558

[56] Vokes EE,Felip E.Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (checkmate 017 and checkmate 057): 3-year update and outcomes in patients with liver metastases.Ann Oncol2018;29:959-65

[57] Escudier B,Sharma P.Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025.Eur Urol2017;72:368-76

[58] Topalian SL,McDermott DF.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol2014;32:1020-30 PMCID:PMC4811023

[59] Weber JS,Minor D.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol2015;16:375-84

[60] Derosa L,Thomas AM.Intestinal akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.Nat Med2022;28:315-24 PMCID:PMC9330544

[61] Gupta KH,Giurini EF,Zloza A.Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy.Vaccines2021;9:1497 PMCID:PMC8707929

[62] Tang Q,Xu B,Chen J.Current status and future directions of bacteria-based immunotherapy.Front Immunol2022;13:911783 PMCID:PMC9226492

[63] Cheng WY,Yu J.The role of gut microbiota in cancer treatment: friend or foe?.Gut2020;69:1867-76 PMCID:PMC7497589

[64] Longhi G,Ventura M.Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer immunotherapy.Front Microbiol2020;11:575072 PMCID:PMC7507897

[65] Sivan A,Hubert N.Commensal bifidobacterium promotes antitumor immunity and facilitates anti-pd-l1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[66] Rong Y,Hong Z.Reactivity toward bifidobacterium longum and enterococcus hirae demonstrate robust CD8⁺ t cell response and better prognosis in hbv-related hepatocellular carcinoma.Exp Cell Res2017;358:352-9

[67] Luu M,Baldrich A.Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.Nat Commun2021;12:4077 PMCID:PMC8249424

[68] Li X,Fan YR.Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth.Cancer Gene Ther2003;10:105-11

[69] Cronin M,Collins SA.High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting.PLoS One2012;7:e30940 PMCID:PMC3266281

[70] D'Amico F,Rampelli S.Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are related to therapeutic outcome.Cancers2021;13:3999 PMCID:PMC8393652

[71] San-Millán I.Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the warburg effect.Carcinogenesis2017;38:119-33 PMCID:PMC5862360

[72] la Cruz-López KG, Castro-Muñoz LJ, Reyes-Hernández DO, García-Carrancá A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches.Front Oncol2019;9:1143 PMCID:PMC6839026

[73] Vinasco K,Kaakoush NO.Microbial carcinogenesis: lactic acid bacteria in gastric cancer.Biochim Biophys Acta Rev Cancer2019;1872:188309

[74] Fidelle M,Alves Costa Silva C.A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.Science2023;380:eabo2296

[75] Sarkar T,Sa G.Tumor-infiltrating t-regulatory cells adapt to altered metabolism to promote tumor-immune escape.Curr Res Immunol2021;2:132-41 PMCID:PMC9040151

[76] Hidalgo-Cantabrana C,Ruiz L,Sánchez B.Bifidobacteria and their health-promoting effects.Microbiol Spectr2017;5(3):

[77] Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP. Synbiotic intervention of bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats.Carcinogenesis2010;31:246-51

[78] Roller M,Collins K,Watzl B.Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients.Br J Nutr2007;97:676-84

[79] Liu Z,Huang M.Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial.BMC Gastroenterol2015;15:34 PMCID:PMC4374379

[80] Liu ZH,Zhang XW.The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial.Am J Clin Nutr2013;97:117-26

[81] Wada M,Saito M.Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.Support Care Cancer2010;18:751-9

[82] Lages PC,Correia MITD.Postoperative symbiotic in patients with head and neck cancer: a double-blind randomised trial.Br J Nutr2018;119:190-5

[83] Suez J,Zilberman-Schapira G.Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT.Cell2018;174:1406-1423.e16

[84] Zmora N,Suez J.Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features.Cell2018;174:1388-1405.e21

[85] Morgan XC,Huttenhower C.Biodiversity and functional genomics in the human microbiome.Trends Genet2013;29:51-8 PMCID:PMC3534939

[86] Bajramagic S,Mulabdic A,Smajlovic SV.Usage of probiotics and its clinical significance at surgically treated patients sufferig from colorectal carcinoma.Med Arch2019;73:316-20 PMCID:PMC6885229

[87] Xie X,Li H.Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients.Nutrition2019;61:132-42

[88] Salminen S,Endo A.The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.Nat Rev Gastroenterol Hepatol2021;18:649-67 PMCID:PMC8387231